Magnetar Financial LLC Buys Shares of 7,460 Moderna, Inc. $MRNA

Magnetar Financial LLC purchased a new position in shares of Moderna, Inc. (NASDAQ:MRNA) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 7,460 shares of the company’s stock, valued at approximately $206,000.

A number of other large investors have also added to or reduced their stakes in the business. Cetera Investment Advisers grew its holdings in Moderna by 20.7% during the 1st quarter. Cetera Investment Advisers now owns 49,215 shares of the company’s stock worth $1,395,000 after acquiring an additional 8,432 shares during the last quarter. HB Wealth Management LLC acquired a new position in shares of Moderna during the first quarter worth $225,000. Empirical Finance LLC grew its stake in shares of Moderna by 7.3% in the first quarter. Empirical Finance LLC now owns 9,215 shares of the company’s stock worth $261,000 after purchasing an additional 624 shares during the last quarter. LPL Financial LLC increased its holdings in Moderna by 83.8% in the first quarter. LPL Financial LLC now owns 676,212 shares of the company’s stock valued at $19,171,000 after purchasing an additional 308,334 shares during the period. Finally, Mackenzie Financial Corp raised its position in Moderna by 14.3% during the 1st quarter. Mackenzie Financial Corp now owns 31,441 shares of the company’s stock worth $891,000 after purchasing an additional 3,922 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Stock Performance

Moderna stock opened at $25.01 on Thursday. The stock has a market capitalization of $9.77 billion, a price-to-earnings ratio of -3.10 and a beta of 2.02. Moderna, Inc. has a 52-week low of $22.28 and a 52-week high of $48.92. The stock’s 50 day moving average price is $25.88 and its two-hundred day moving average price is $26.97.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.15) by $1.64. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $893.29 million. Moderna had a negative net margin of 139.61% and a negative return on equity of 29.81%. Moderna’s quarterly revenue was down 45.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.03 EPS. Moderna has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that Moderna, Inc. will post -9.61 EPS for the current year.

Wall Street Analysts Forecast Growth

MRNA has been the topic of a number of analyst reports. Berenberg Bank set a $28.00 price target on Moderna in a research report on Monday, November 17th. Barclays reduced their target price on Moderna from $31.00 to $25.00 and set an “equal weight” rating on the stock in a report on Friday, November 7th. Citigroup lowered their price target on shares of Moderna from $30.00 to $28.00 and set a “neutral” rating for the company in a report on Thursday, October 23rd. JPMorgan Chase & Co. dropped their price target on shares of Moderna from $26.00 to $25.00 and set an “underweight” rating on the stock in a research report on Thursday, October 23rd. Finally, UBS Group reiterated a “buy” rating on shares of Moderna in a research report on Friday, November 21st. Two analysts have rated the stock with a Buy rating, twelve have given a Hold rating and five have given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus target price of $29.46.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.